Featured Letters, Testimony, & Comments
BIO Comments to FDA (Docket No. FDA-2023-N-0398)…
In these comments, BIO addresses FDA’s four specific topic areas of consideration as the agency develops its draft guidance per PDUFA VII.
Letter in support of U.S. Codex Office funding
BIO joined with more than 40 groups in calling on Congress to set 2024 funding for the U.S. Codex Office at or above the 2023 level.
BIO Comments to the FDA on Clinical Trial…
BIO’s comments support accelerated approval as an important regulatory pathway that allows patients with serious and life-threatening illnesses such as cancer to have earlier access to promising therapies.